On 12 December 2025, the US FDA approved Nuzolvence® (zoliflodacin), a first-in-class oral antibiotic for gonorrhoea developed by GARDP and Innoviva Specialty Therapeutics (IST). Media outlets around the world covered the news.

New antibiotics hailed as ‘turning point’ in treating drug-resistant gonorrhoea

 

New gonorrhea drug is not just a scientific breakthrough but a business one

FDA Approves First New Gonorrhoea Treatment in Decades Amid Rising Antibiotic Resistance

 

F.D.A. Approves Two New Drugs to Treat Gonorrhea

 

FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance

 

US FDA approves Innoviva’s oral antibiotic for gonorrhea

 

Pharma major Dr. Reddy’s to produce and market drug for gonorrhoea granted approval by U.S. FDA

 

New antibiotics for gonorrhea could help beat back drug-resistant infections

 

New antibiotic could stave off drug-resistant gonorrhoea

 

FDA approves first new kind of drug to target gonorrhea in decades

 

With strong phase 3 findings, a new antibiotic for gonorrhea is on the horizon

 

FDA endorses 2nd new gonorrhea treatment, clearing way for Innoviva’s Nuzolvence

 

Why the approval of two new gonorrhoea treatments is a game changer

 

りん病の新たな抗菌薬、数十年ぶりに承認　世界初の飲み薬